Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen

Yu Quan Wei, Mei Juan Huang, Li Yang, Xia Zhao, Ling Tian, You Lu, Jing Mei Shu, Chong Jiu Lu, Ting Niu, Bin Kang, Yun Qiu Mao, Fen Liu, Yan Jun Wen, Shong Lei, Feng Luo, Li Qun Zhou, Feng Peng, Yu Jiang, Ji Yan Liu, Hao Zhou & 11 others Qing Ru Wang, Qiu Ming He, Fei Xiao, Yanyan Lou, Xing Jiang Xie, Qiu Li, Yang Wu, Zhen Yu Ding, Bin Hu, Min Hu, Wei Zhang

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Overcoming immune tolerance of the growth factors associated with tumor growth should be a useful approach to cancer therapy by active immunity. We used vascular endothelial growth factor (VEGF) as a model antigen to explore the feasibility of the immunogene tumor therapy with a vaccine based on a single xenogeneic homologous gene, targeting the growth factors associated with angiogenesis. To test this concept, we constructed a plasmid DNA encoding Xenopus homologous VEGF (XVEGF-p) and control vectors. We found that immunogene tumor therapy with a vaccine based on XVEGF was effective at both protective and therapeutic antitumor immunity in several tumor models in mice. VEGF-specific autoantibodies in sera of mice immunized with XVEGF-p could be found in Western blotting analysis and ELISA assay. The purified immunoglobulins were effective at the inhibition of VEGF-mediated endothelial cell proliferation in vitro, and at antitumor activity and the inhibition of angiogenesis by adoptive transfer in vivo. The elevation of VEGF in the sera of the tumor-bearing mice could be abrogated with XVEGF-p immunization. The antitumor activity and production of VEGF-specific autoantibodies, significantly elevated IgG1 and IgG2b, could be abrogated by the depletion of CD4+ T lymphocytes. The observations may provide a vaccine strategy for cancer therapy through the induction of autoimmunity against the growth factors associated with tumor growth in a cross reaction with single xenogeneic homologous gene and may be of importance in the further exploration of the applications of other xenogeneic homologous genes identified in human and other animal genome sequence projects in cancer therapy.

Original languageEnglish (US)
Pages (from-to)11545-11550
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume98
Issue number20
DOIs
StatePublished - Sep 25 2001
Externally publishedYes

Fingerprint

Cancer Vaccines
Xenopus
Vascular Endothelial Growth Factor A
Antigens
Neoplasms
Intercellular Signaling Peptides and Proteins
Therapeutics
Autoantibodies
Vaccines
Active Immunity
Immune Tolerance
Gene Targeting
Adoptive Transfer
Cross Reactions
Growth
Serum
Autoimmunity
Genes
Immunoglobulins
Immunity

ASJC Scopus subject areas

  • General

Cite this

Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. / Wei, Yu Quan; Huang, Mei Juan; Yang, Li; Zhao, Xia; Tian, Ling; Lu, You; Shu, Jing Mei; Lu, Chong Jiu; Niu, Ting; Kang, Bin; Mao, Yun Qiu; Liu, Fen; Wen, Yan Jun; Lei, Shong; Luo, Feng; Zhou, Li Qun; Peng, Feng; Jiang, Yu; Liu, Ji Yan; Zhou, Hao; Wang, Qing Ru; He, Qiu Ming; Xiao, Fei; Lou, Yanyan; Xie, Xing Jiang; Li, Qiu; Wu, Yang; Ding, Zhen Yu; Hu, Bin; Hu, Min; Zhang, Wei.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 98, No. 20, 25.09.2001, p. 11545-11550.

Research output: Contribution to journalArticle

Wei, YQ, Huang, MJ, Yang, L, Zhao, X, Tian, L, Lu, Y, Shu, JM, Lu, CJ, Niu, T, Kang, B, Mao, YQ, Liu, F, Wen, YJ, Lei, S, Luo, F, Zhou, LQ, Peng, F, Jiang, Y, Liu, JY, Zhou, H, Wang, QR, He, QM, Xiao, F, Lou, Y, Xie, XJ, Li, Q, Wu, Y, Ding, ZY, Hu, B, Hu, M & Zhang, W 2001, 'Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen', Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 20, pp. 11545-11550. https://doi.org/10.1073/pnas.191112198
Wei, Yu Quan ; Huang, Mei Juan ; Yang, Li ; Zhao, Xia ; Tian, Ling ; Lu, You ; Shu, Jing Mei ; Lu, Chong Jiu ; Niu, Ting ; Kang, Bin ; Mao, Yun Qiu ; Liu, Fen ; Wen, Yan Jun ; Lei, Shong ; Luo, Feng ; Zhou, Li Qun ; Peng, Feng ; Jiang, Yu ; Liu, Ji Yan ; Zhou, Hao ; Wang, Qing Ru ; He, Qiu Ming ; Xiao, Fei ; Lou, Yanyan ; Xie, Xing Jiang ; Li, Qiu ; Wu, Yang ; Ding, Zhen Yu ; Hu, Bin ; Hu, Min ; Zhang, Wei. / Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. In: Proceedings of the National Academy of Sciences of the United States of America. 2001 ; Vol. 98, No. 20. pp. 11545-11550.
@article{c3e63a59b019413aaec7c81a3a0078c6,
title = "Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen",
abstract = "Overcoming immune tolerance of the growth factors associated with tumor growth should be a useful approach to cancer therapy by active immunity. We used vascular endothelial growth factor (VEGF) as a model antigen to explore the feasibility of the immunogene tumor therapy with a vaccine based on a single xenogeneic homologous gene, targeting the growth factors associated with angiogenesis. To test this concept, we constructed a plasmid DNA encoding Xenopus homologous VEGF (XVEGF-p) and control vectors. We found that immunogene tumor therapy with a vaccine based on XVEGF was effective at both protective and therapeutic antitumor immunity in several tumor models in mice. VEGF-specific autoantibodies in sera of mice immunized with XVEGF-p could be found in Western blotting analysis and ELISA assay. The purified immunoglobulins were effective at the inhibition of VEGF-mediated endothelial cell proliferation in vitro, and at antitumor activity and the inhibition of angiogenesis by adoptive transfer in vivo. The elevation of VEGF in the sera of the tumor-bearing mice could be abrogated with XVEGF-p immunization. The antitumor activity and production of VEGF-specific autoantibodies, significantly elevated IgG1 and IgG2b, could be abrogated by the depletion of CD4+ T lymphocytes. The observations may provide a vaccine strategy for cancer therapy through the induction of autoimmunity against the growth factors associated with tumor growth in a cross reaction with single xenogeneic homologous gene and may be of importance in the further exploration of the applications of other xenogeneic homologous genes identified in human and other animal genome sequence projects in cancer therapy.",
author = "Wei, {Yu Quan} and Huang, {Mei Juan} and Li Yang and Xia Zhao and Ling Tian and You Lu and Shu, {Jing Mei} and Lu, {Chong Jiu} and Ting Niu and Bin Kang and Mao, {Yun Qiu} and Fen Liu and Wen, {Yan Jun} and Shong Lei and Feng Luo and Zhou, {Li Qun} and Feng Peng and Yu Jiang and Liu, {Ji Yan} and Hao Zhou and Wang, {Qing Ru} and He, {Qiu Ming} and Fei Xiao and Yanyan Lou and Xie, {Xing Jiang} and Qiu Li and Yang Wu and Ding, {Zhen Yu} and Bin Hu and Min Hu and Wei Zhang",
year = "2001",
month = "9",
day = "25",
doi = "10.1073/pnas.191112198",
language = "English (US)",
volume = "98",
pages = "11545--11550",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "20",

}

TY - JOUR

T1 - Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen

AU - Wei, Yu Quan

AU - Huang, Mei Juan

AU - Yang, Li

AU - Zhao, Xia

AU - Tian, Ling

AU - Lu, You

AU - Shu, Jing Mei

AU - Lu, Chong Jiu

AU - Niu, Ting

AU - Kang, Bin

AU - Mao, Yun Qiu

AU - Liu, Fen

AU - Wen, Yan Jun

AU - Lei, Shong

AU - Luo, Feng

AU - Zhou, Li Qun

AU - Peng, Feng

AU - Jiang, Yu

AU - Liu, Ji Yan

AU - Zhou, Hao

AU - Wang, Qing Ru

AU - He, Qiu Ming

AU - Xiao, Fei

AU - Lou, Yanyan

AU - Xie, Xing Jiang

AU - Li, Qiu

AU - Wu, Yang

AU - Ding, Zhen Yu

AU - Hu, Bin

AU - Hu, Min

AU - Zhang, Wei

PY - 2001/9/25

Y1 - 2001/9/25

N2 - Overcoming immune tolerance of the growth factors associated with tumor growth should be a useful approach to cancer therapy by active immunity. We used vascular endothelial growth factor (VEGF) as a model antigen to explore the feasibility of the immunogene tumor therapy with a vaccine based on a single xenogeneic homologous gene, targeting the growth factors associated with angiogenesis. To test this concept, we constructed a plasmid DNA encoding Xenopus homologous VEGF (XVEGF-p) and control vectors. We found that immunogene tumor therapy with a vaccine based on XVEGF was effective at both protective and therapeutic antitumor immunity in several tumor models in mice. VEGF-specific autoantibodies in sera of mice immunized with XVEGF-p could be found in Western blotting analysis and ELISA assay. The purified immunoglobulins were effective at the inhibition of VEGF-mediated endothelial cell proliferation in vitro, and at antitumor activity and the inhibition of angiogenesis by adoptive transfer in vivo. The elevation of VEGF in the sera of the tumor-bearing mice could be abrogated with XVEGF-p immunization. The antitumor activity and production of VEGF-specific autoantibodies, significantly elevated IgG1 and IgG2b, could be abrogated by the depletion of CD4+ T lymphocytes. The observations may provide a vaccine strategy for cancer therapy through the induction of autoimmunity against the growth factors associated with tumor growth in a cross reaction with single xenogeneic homologous gene and may be of importance in the further exploration of the applications of other xenogeneic homologous genes identified in human and other animal genome sequence projects in cancer therapy.

AB - Overcoming immune tolerance of the growth factors associated with tumor growth should be a useful approach to cancer therapy by active immunity. We used vascular endothelial growth factor (VEGF) as a model antigen to explore the feasibility of the immunogene tumor therapy with a vaccine based on a single xenogeneic homologous gene, targeting the growth factors associated with angiogenesis. To test this concept, we constructed a plasmid DNA encoding Xenopus homologous VEGF (XVEGF-p) and control vectors. We found that immunogene tumor therapy with a vaccine based on XVEGF was effective at both protective and therapeutic antitumor immunity in several tumor models in mice. VEGF-specific autoantibodies in sera of mice immunized with XVEGF-p could be found in Western blotting analysis and ELISA assay. The purified immunoglobulins were effective at the inhibition of VEGF-mediated endothelial cell proliferation in vitro, and at antitumor activity and the inhibition of angiogenesis by adoptive transfer in vivo. The elevation of VEGF in the sera of the tumor-bearing mice could be abrogated with XVEGF-p immunization. The antitumor activity and production of VEGF-specific autoantibodies, significantly elevated IgG1 and IgG2b, could be abrogated by the depletion of CD4+ T lymphocytes. The observations may provide a vaccine strategy for cancer therapy through the induction of autoimmunity against the growth factors associated with tumor growth in a cross reaction with single xenogeneic homologous gene and may be of importance in the further exploration of the applications of other xenogeneic homologous genes identified in human and other animal genome sequence projects in cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=0035949593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035949593&partnerID=8YFLogxK

U2 - 10.1073/pnas.191112198

DO - 10.1073/pnas.191112198

M3 - Article

VL - 98

SP - 11545

EP - 11550

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 20

ER -